Background {#s0005}
==========

COVID-19 {#s0010}
--------

A novel coronavirus emerged in December 2019, which has spread rapidly across the world causing a pandemic which was never observed in history with the viruses of this family [@b0005], [@b0010]. The virus is a new member of the lineage b of the genus *Betacoronavirus* and it also has similarity with the 2002 severe acute respiratory syndrome virus SARS-CoV. Therefore, it is named as SARS-CoV-2 by WHO. The respiratory disease caused by the virus was designated as coronavirus disease 2019 (COVID-19) [Fig. 1.](#f0005){ref-type="fig"} .Fig. 1Under normal conditions, host enzyme Furin activates receptor binding domain (RBD) of SARS-CoV-2 S protein, and this activated RBD binds to host cell membrane receptor ACE2, ultimately leading to fusion of viral particles with host cell membrane, facilitating viral entry into host tissue. In case of oral cancer, increased expression of Furin leads to activation of S protein RBD of a greater number of SARS-CoV-2 and increased expression of ACE2 facilitates binding of a greater number of SARS-CoV-2, ultimately increasing the chances of infection and its severity.

SARS-CoV-2 is transmitted directly through cough, sneeze, droplet inhalation and indirectly through contact of oral, nasal, and eye mucous membranes via hand, contaminated with live virus [@b0015]. This virus can also be transmitted directly or indirectly through saliva. This suggests that oral cavity is one of the sites which are more susceptible to be exposed to SARS-CoV-2.

Role of ACE2 and Furin in COVID-19 {#s0015}
----------------------------------

Coronaviruses (CoVs) are a family of enveloped, single-stranded positive-sense RNA viruses and are able to infect a wide range of mammalian and avian species, causing respiratory or enteric diseases [@b0020]. CoVs have a major surface protein denoted as the spike (S) protein, which facilitates the infection by binding to host cellular receptors and ultimately leading to the fusion of the viral lipid envelope with host cellular membranes. Before binding to the host receptor, the S protein is activated by host proteases [@b0025].

Various structural studies and experimental data revealed two most important features of S protein in SARS-CoV-2:i.It has receptor-binding domain (RBD) which is optimized for binding to human receptor ACE2 (Angiotensin-converting enzyme 2) [@b0030], [@b0035], [@b0040], [@b0045]. ACE-2 is a type I transmembrane metallocarboxypeptidase mainly found attached to the outer surface of the lungs, arteries, heart, kidney, and intestines. It plays a key role in the Renin-Angiotensin System (RAS) and is targeted for the treatment of hypertension [@b0050]. ACE2 degrades Angiotensin II to generate Angiotensin 1--7, thereby, negatively regulating RAS [@b0055], [@b0060].ii.It also has a functional polybasic cleavage site (RRAR) at the junction of S1 and S2, the two subunits of the S protein [@b0035]. This site allows effective activation of S protein by a host proprotein convertase Furin. Furin is a calcium dependent membrane bound protease which is expressed ubiquitously as a 794 amino acid zymogen that undergoes autocatalytic cleavage to become fully active [@b0065], [@b0070].

It suggests that host ACE-2 and Furin are the most crucial proteins involved in COVID-19 infection.

Overexpression of Furin in oral cancer {#s0020}
--------------------------------------

Increased expression of Furin was documented in various cancer types and Furin is involved in most cancer hallmark processes like cell proliferation, migration and invasion or neo-vascularization. Overexpression of Furin was correlated with aggressiveness of cancer and proposed marker for advanced or high‐grade disease. Cicco et al. confirmed increased expression of Furin in approximately 90% of oral squamous cell carcinoma (OSCC) and in all squamous cell carcinoma of the oesophagus analyzed using microarray technology [@b0075]. Furin expression was found to be significantly higher in most precursor lesions and OSCC than in normal epithelia [@b0080]. Also, in post radiotherapy recurrent laryngeal cancers, it was observed that Furin expression was higher in samples obtained after radiation, this suggests radiation induced overexpression of Furin in recurrent or resistant cancers [@b0085]. In addition to these, various other studies have demonstrated increased expression of Furin in oral cancer [@b0090], [@b0095].

Expression of ACE2 in oral cancer {#s0025}
---------------------------------

While analysing RNAseq data from the public database, Xu et al. [@b0100] reported in a recent article that paracarcinoma and normal tissues express high ACE2 in oral buccal and gingiva tissue. Single-cell RNAseq data from patients' oral tissue by them also suggested that ACE2 were highly enriched in epithelial cells of tongue. Liu, L. previously demonstrated in animal model that epithelial cells layer of salivary gland ducts are early target cells of severe acute respiratory syndrome coronavirus infection in the upper respiratory tracts through their over expressed ACE2 [@b0105]. Featherston et al. observed that ACE expression, which is homologous to ACE2, was higher in cancer stem cells of moderately differentiated buccal mucosal squamous cell carcinoma [@b0110]. In laryngeal cancer, ACE was also found to be upregulated [@b0115].

Hypothesis {#s0030}
==========

As it is evident from the recent studies that SARS-CoV-2 requires host enzyme Furin to activate receptor binding domain of its S protein and ACE2 is required as binding receptor, facilitating the entry of virus in the host cell. It is also recited in literature that oral cancer tissue express higher level of Furin and ACE2 and oral cavity is one of the most exposed tissue for SARS CoV2 infection. Therefore, an hypothesis arises which states that oral cancer patients may be more susceptible to SARS CoV2 infection. Also, they have higher expression of Furin and ACE2, allowing entry of a large number of viruses at a time, leading to increased viral load in the patients with oral cancer. This ultimately leads to poor prognosis of COVID-19 in these patients.

Evaluation of the hypothesis {#s0035}
============================

Multiple studies suggested that there is overexpression of host Furin in oral cancer, which is a key enzyme to activate the Furin like cleavage site present in the S spike of SARS CoV2 leaving to gain of function in attaching the viral particles with its receptors like ACE2 [@b0120], [@b0125]. However, there is limited data on overexpression of Furin in oral cancers of different geographical regions. Another limitation is that Furin overexpression was analyzed in a relatively less number of samples. Again, there is very limited scientific literature available regarding oral cancer and COVID19. So, it is evident that studies with larger sample size is required to substantiate the overexpression of Furin in oral cancer tissue along with its mechanistic reasoning.

ACE (homologue for ACE2) overexpression was demonstrated in oral cancers. There is also evidence from available database that ACE 2 mRNA is over-expressed in para-carcinoma as well as normal cells in oral mucosa. However, studies showing ACE2 expression at mRNA as well as protein level in cancer cells are not available in literature. Hence, studies are required to analyze the expression of ACE2 in oral cancer tissue.

Observational as well as epidemiological studies are mandatory which can reveal the frequency of oral cancer patients infected with COVID-19 and how the prognosis of these patients differ from the control population.

Furthermore, in one of the studies, it was observed that radiotherapy induced the increased expression of Furin [@b0090]. Therefore, more extensive studies are needed to analyze the susceptibility of oral cancer patients undergoing radiotherapy for COVID-19 infection.

Overall, till now, there is limited data to evidently prove this substantial hypothesis. However, in our opinion, evidence of our hypothesis will be soon substantiated with the more data published in scientific literature.

Consequences of hypothesis and discussion {#s0040}
=========================================

More serious infection {#s0045}
----------------------

Oral cancer tissues express higher levels of Furin, while paratumour oral tissue expresses high ACE2, key proteins mandatory for SARS CoV2 infection. Therefore, oral cancer patients are more susceptible to this infection as compared to normal population as over expression of Furin will increase more conversion of S protein of the virus particle, which will attach in greater number to overexpressed ACE2 and finally increased and easy entrapment of the viral particles into the cells. Moreover, these patients are more prone to SARS CoV2 reinfection leading to viremia which is also a challenge to treat. Furthermore, most oral cancer patients are older males which themselves are two independent risk factors for COVID19. Again, older age is associated with reduced immune state, further increasing the chances of SARS CoV2infection and its severity.

Multilevel risks COVID-19 on oral cancer patients {#s0050}
-------------------------------------------------

In our opinion, during the COVID-19 pandemic, it would be more practical to give extra attention to oral cancer patients during COVID-19 pandemic and re-evaluation of current treatment paradigms in oral oncology is also needed as suggested by Day et al in a recent article [@b0130]. They very aptly suggested that there are increased multilevel risks to patients, surgeons, health care workers (HCWs), institutions and even to society due to positive COVID19 oral patients. It is suggested that the nonsurgical management outweighs the surgical management under this unprecedented pandemic situation, even though there is a chance of radiotherapy induce Furin expression in resistant cancers. Thus, comprehensive risk benefit ratio needs to be developed in managing the Oral Cancer patients with SARS-CoV2 infection.
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